Your browser does not support flash 8 or later which is needed to view this animation. Please visit www.macromedia.com/go/getflashplayer to download the flash player.

1. Llovet JM, Ricci S, Mazzaferro V, et al; for the SHARP Investigators Study Group. Sorafenib in Advanced Hepatocellular Carcinoma. [accepted for publication].
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
3. Moradpour D, Blum HE. Pathogenesis of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2005;17:477-483.
4. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340(10):745-750.
5. Llovet JM, Fuster J, Bruix J; for the Barcelona Clinic Liver Cancer (BCLC) Group. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434-1440.
6. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 suppl 1):S35-S50.
7. Llovet JM, Burroughs A, Bruix J. Seminar: hepatocellular carcinoma. Lancet. 2003;362:1907-1917.
8. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19(3):271-285.
9. Llovet J, Ricci S, Mazzaferro V, et al; for the SHARP Investigators Study Group. Sorafenib improves survival in hepatocellular carcinoma: results of a phase III randomized, placebo-controlled trial. Paper presented at: 2007 ASCO Annual Meeting; June 4, 2007; Chicago, Ill.
10. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg.1973;60(8):646-649.

Next: HCC Clinical Experience Presentations

 

Term

Explanation for term.